SISCAPA Assay Technologies | GenomeWeb

SISCAPA Assay Technologies

The company plans to launch the 12-protein panel as a CLIA test for longitudinal monitoring of cardiovascular disease, kidney disease, and diabetes.

While much attention has focused on triple quads, MALDI-TOFs offer advantages in simplicity and throughput that could help them make clinical inroads.

The company plans to offer the immuno-MRM assays as kits covering sample prep and protein digestion as well as immuno-enrichment of specific peptides.

Having gained traction for its technology in the RUO and LDT spaces, the company is now looking to develop its reagents for use in regulatory-cleared IVDs.

NEW YORK (GenomeWeb) – Precision Antibody in partnership with SISCAPA Assay Technologies has completed a Phase I SBIR contract from the National Cancer Institute to develop antibodies for mass spec-based protein biomarker assays.

NEW YORK (GenomeWeb) – New England Peptide and SISCAPA Assay Technologies are collaborating to manufacture and sell stable isotope standard peptides for use in SISCAPA's protein quantification assays.

NEW YORK (GenomeWeb) – Agilent Technologies and SISCAPA Assay Technologies said today that they have signed a non-exclusive agreement to provide complete workflows for targeted protein quantitation.

NEW YORK (GenomeWeb) – SISCAPA Assay Technologies said this week that it has closed a Series A financing round.

SISCAPA Assay Technologies has appoint Gustavo Salem president and CEO.
Salem was previously an SAT board member. Prior to that he was VP and general manager of the Biological Systems Division at Agilent as well as president and CEO of Assay Designs.

Mayo Medical Laboratories said this week that it has begun offering mass spec-based serum thyroglobulin testing using SISCAPA technology.

Pages

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.